BiotechTube
Home/Pipeline/ABBV-951

ABBV-951

Parkinson's Disease

ApprovedPost-Marketing Study

Key Facts

Indication
Parkinson's Disease
Phase
Approved
Status
Post-Marketing Study
Company
AbbVie

About AbbVie

AbbVie's mission is to discover and deliver transformative medicines that solve serious health issues. Its landmark achievement was building the world's top-selling drug, Humira, into a franchise while successfully navigating its patent expiry through a robust pipeline and strategic acquisitions like Allergan. The company's strategy hinges on sustained leadership in immunology, accelerated growth in oncology and neuroscience, and financial discipline to fuel high R&D investment and shareholder returns.

View full company profile

Therapeutic Areas

ImmunologyOncologyNeuroscienceEye CareVirology

Other Parkinson's Disease Drugs

DrugCompanyPhase
NPT200-11Neuropore TherapiesPhase 1
NUZ-001Neurizon TherapeuticsPreclinical
VXX-301VaxxinityPreclinical
BAN2802BioArcticPhase 1
CNM-Au8ClenePhase 2
hpSC-Derived Neural/Dopaminergic CellsInternational Stem CellPreclinical/Early Clinical
SLS-004Seelos TherapeuticsPreclinical
SLS-007Seelos TherapeuticsPreclinical
Parkinson's Disease Portfolio (Platform-derived)WD PharmaceuticalNot Disclosed (Likely Preclinical/Early Clinical)
UX-DA001UniXellPhase 1
Parkinson's Disease ResearchProgenaBiomeResearch
A9 Dopaminergic Neuron TherapyTrailhead BiosystemsPre-clinical